TG Therapeutics’ umbralisib, ublituximab likely to face market hurdles but FDA approval highly expected

TG Therapeutics
Analysts believe umbralisib and U2 will gain an FDA nod based on data released at the recent American Society of Hematology (ASH) virtual conference. Credit: Ed Uthman.